Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559869 · ClinicalTrials.gov registry record
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
A clinical trial of Amyotrophic Lateral Sclerosis (ALS), sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 86
- Enrollment target
- 2
- Study locations
NCT02559869 is a study of Amyotrophic Lateral Sclerosis (ALS) that has completed, run by Massachusetts General Hospital. The registered enrollment target is 86 participants, below the 256-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02559869, a study of Amyotrophic Lateral Sclerosis (ALS), has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to produce imaging tools that will allow researchers to conduct future ALS clinical trials more efficiently which may in turn impact the pace for ALS drug discovery.
Conditions Studied
Interventions
- DRUG [18F] GE-180
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- Houston Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-06-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02559869
The ClinicalTrials.gov registry entry for NCT02559869 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (66% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 1 intervention - of which [18F] GE-180 is the first listed.
NCT02559869 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT02559869 about?
NCT02559869 is a clinical study titled "Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis". This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to pr...
What is the current status of trial NCT02559869?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2015-11. Estimated completion is 2019-06-28.
What conditions does trial NCT02559869 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT02559869?
The interventions under investigation include: [18F] GE-180 (DRUG).
Who is sponsoring clinical trial NCT02559869?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02559869 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
-
Healing ALS Registry Observational Study (HAROS)
RECRUITING
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
RECRUITING · Phase 1
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.